Cue Biopharma, Inc. vs. Eli Lilly & Co.
Eli Lilly & Co. (LLY) comes out ahead, leading on 6 of 8 compared factors.
Size & Scale
| CUE | LLY | |
|---|---|---|
| Market Cap | $269.15 million | $1.04 trillion |
| Revenue (TTM) | $37.65 million | $79.67 billion |
| Net Income (TTM) | $-164,108,000 | $26.71 billion |
LLY leads on 3 of 3 size & scale factors.
Valuation
| CUE | LLY | |
|---|---|---|
| P/E Ratio | — | 39.28 |
| Price / Book | 116.51 | 30.65 |
| Price / Sales | 7.15 | 13.03 |
CUE and LLY split the valuation factors evenly.
Profitability
| CUE | LLY | |
|---|---|---|
| Net Margin | -435.83% | 33.53% |
| Return on Equity | -7104.24% | 78.84% |
LLY leads on 2 of 2 profitability factors.
Dividend
| CUE | LLY | |
|---|---|---|
| Dividend Yield | — | 0.59% |
| Payout Ratio | — | 23.23 |
CUE and LLY split the dividend factors evenly.
Risk & Sentiment
| CUE | LLY | |
|---|---|---|
| Short Interest | 0.48% | 1.29% |
CUE leads on 1 of 1 risk & sentiment factors.
Dig deeper: CUE overview, CUE financials, LLY overview, LLY financials.
Comparisons use delayed, cached fundamental data and cover only the factors shown. For informational purposes only — not investment advice.